Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06950957

Video Laryngeal Mask vs. Endotracheal Tube in Septoplasty

This randomized controlled trial compares a video laryngeal mask airway (VLMA) and an endotracheal tube (ETT) in adult patients undergoing elective septoplasty. The primary objective is to see which device more effectively prevents surgical blood contamination in the glottic and subglottic regions. The study also assesses perioperative hemodynamic stability, ventilation parameters, and postoperative recovery factors such as sore throat, hoarseness, and overall patient comfort. The findings aim to help determine the optimal airway device choice for nasal surgeries.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Airway Complication of Anesthesia Anesthesia Intubation Complication Septoplasty

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Samsun University, Samsun Training and Research Hospital

Samsun, Ilkadim, 55000, Turkey (Türkiye)

Location status: Recruiting

About this study

This prospective, randomized controlled trial will compare the efficacy and safety of a video laryngeal mask airway (VLMA) versus a standard endotracheal tube (ETT) for airway management in adult patients (aged 18-65, ASA physical status I-II) undergoing elective septoplasty under general anesthesia.

Participants will be randomly assigned to receive either a video-assisted supraglottic airway (VLMA) or a conventional endotracheal tube (ETT). The primary objective is to evaluate whether VLMA can provide better protection against blood contamination in the glottic and subglottic regions compared to ETT. Secondary objectives include assessments of perioperative hemodynamic stability, respiratory performance, postoperative airway-related complications, and overall recovery.

All patients will undergo standardized anesthesia induction (e.g., propofol plus an opioid) and maintenance with inhalational agents and/or remifentanil infusion. Depth of anesthesia will be monitored using the bispectral index (BIS), along with standard ASA monitoring. Respiratory parameters (tidal volume, end-tidal CO₂, peak and plateau airway pressures) will be recorded throughout the procedure. Hemodynamic data (heart rate, systolic and diastolic arterial pressures) will be measured at predefined time points: pre-induction, post-airway insertion, and post-extubation.

At the end of surgery, blood contamination within the airway will be assessed at two anatomical levels:

Distal trachea: In both groups, a fiberoptic bronchoscope will be used for evaluation. In the ETT group, the bronchoscope will be inserted through the endotracheal tube before removal. In the VLMA group, the bronchoscope will be passed through the lumen of the VLMA prior to removal.

Glottis/tracheal inlet: This region will be assessed only in the VLMA group, using the device's integrated video camera to obtain a direct visual inspection before removal.

A standardized four-point scale adapted from Kaplan et al. will be used to rate the degree of blood contamination:

  • = No visible blood,
  • = Mild contamination,
  • = Moderate contamination,
  • = Severe contamination with diffuse blood.

Following airway device removal, all patients will be transferred to the post-anesthesia care unit (PACU) and monitored until achieving an acceptable Aldrete score. Postoperative airway-related symptoms-such as sore throat, hoarseness, dysphagia, and cough-will be assessed at 2, 8, 12, 24, and 48 hours. Additional data including total anesthesia duration, airway insertion time, and any adverse events (e.g., laryngospasm, bronchospasm, desaturation, or need for airway repositioning) will also be documented.

This study aims to determine whether VLMA offers advantages over ETT in terms of airway protection, intraoperative stability, and postoperative comfort in septoplasty surgery.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ASA I-II classification patients
  • Patients aged 18-65 years undergoing elective septoplasty

Exclusion criteria

  • ASA III-IV classification patients
  • Patients with anticipated difficult airway
  • Patients under 18 years of age
  • History of gastroesophageal reflux disease (GERD) or hiatal hernia
  • Body mass index (BMI) >30
  • Pregnant patients

Treatment and study plan

Video Laryngeal Mask Airway (VLMA)

Device

A second-generation supraglottic airway device with an integrated video camera, used for airway management in adult patients undergoing elective septoplasty. The device allows real-time visualization of the glottic inlet to identify blood infiltration or anatomical challenges. Prior to removal, a fiberoptic bronchoscope will be introduced through the device's lumen to assess the distal trachea for blood contamination. Parameters such as airway insertion time, ventilation mechanics, hemodynamic data, analgesic requirements, and postoperative recovery scores (e.g., Aldrete score, sore throat incidence) will be recorded and analyzed.

Endotracheal tube (ETT)

Device

A standard cuffed endotracheal tube inserted using direct laryngoscopy, employed for airway management during elective septoplasty. At the end of surgery, a fiberoptic bronchoscope will be passed through the ETT to evaluate the distal trachea for blood contamination. Airway insertion time, ventilation parameters, intraoperative hemodynamics, analgesic use, and postoperative outcomes (including sore throat and recovery scores) will be documented and compared with the VLMA group to assess differences in airway safety and clinical performance.

Primary outcomes

  1. Glottis/Trachea and Distal Trachea Blood Contamination Scores

    Time frame: Evaluated once at the conclusion of surgery, immediately prior to device removal (approximately 60-120 minutes after anesthesia induction).

    The presence of blood contamination will be evaluated separately at two distinct airway sites:

    Distal trachea: Both SaCoVLM and ETT groups will undergo fiberoptic bronchoscopic evaluation for blood contamination in the distal trachea immediately before removal of the airway device at the end of surgery.

    Glottis/tracheal inlet: This area will be visually assessed only in the SaCoVLM group using the integrated camera of the video laryngeal mask immediately prior to device removal at the end of surgery.

    A standardized 4-point scale will be used for both assessments:

    • = No blood contamination
    • = Mild amount of blood contamination (trace amounts)
    • = Moderate amount of blood contamination
    • = Severe amount of blood contamination

Secondary outcomes

  1. Heart Rate (HR)

    Time frame: From preoperative baseline until arrival to the recovery unit (approximately 120 minutes).

    Heart rate (beats per minute) will be recorded at the following time points: pre-operative baseline; immediately after induction of anesthesia; at 1, 3, 5, 10, 15, and 30 minutes after airway-device insertion; and at 5 minutes after extubation.

  2. Postoperative Sore Throat (POST Score)

    Time frame: Up to 48 hours postoperatively.

    he severity of postoperative sore throat (POST) will be assessed using a standardized scoring system immediately after extubation, upon arrival to the recovery room, and at 2, 8, 12, 24, and 48 hours postoperatively. The score is based on patient-reported discomfort and classified as follows: 0: No sore throat

    • Mild discomfort (less than a common cold)
    • Moderate discomfort (as bad as a common cold)
    • Severe discomfort interfering with daily activities The assessment will be conducted through direct patient questioning at each designated time point.

  3. Arterial Blood Pressure (Systolic, Diastolic, and Mean)

    Time frame: From preoperative baseline until arrival to the recovery unit (approximately 120 minutes).

    Systolic, diastolic, and mean arterial blood pressures (mmHg) will be recorded at the following time points: pre-operative baseline; immediately after induction of anesthesia; at 1, 3, 5, 10, 15, and 30 minutes after airway-device insertion; and at 5 minutes after extubation.

  4. Total Remifentanil Consumption

    Time frame: Intraoperative

    Total remifentanil dose (mcg) administered during surgery will be compared between groups.

  5. Airway Insertion Time

    Time frame: Immediately after induction of anesthesia

    The time required to successfully place the assigned airway device (VLMA or ETT), measured from the moment the device is picked up until effective ventilation is confirmed via capnography and chest rise. This outcome evaluates the ease and efficiency of airway device placement.

  6. Intraoperative Airway Complications

    Time frame: From induction of anesthesia to extubation (intraoperative period)

    Incidence of intraoperative airway complications such as bronchospasm, laryngospasm, airway obstruction, or intraoperative desaturation episodes (SpO₂ <90%) will be systematically recorded.

  7. Postoperative Dysphagia (Swallowing Difficulty)

    Time frame: Up to 48 hours postoperatively.

    Presence or absence of swallowing difficulty (dysphagia) will be evaluated immediately after extubation, upon arrival to the recovery room, and at 2, 8, 12, 24, and 48 hours postoperatively using direct patient questioning.

  8. First-Attempt Success Rate of Airway Device Insertion

    Time frame: Immediately after induction of anesthesia.

    Comparison of the success rate of airway device insertion (VLMA or ETT) at the first attempt. Additionally, the total number of insertion attempts required for successful placement will be evaluated.

  9. Postoperative Nausea and Vomiting (PONV)

    Time frame: Up to 48 hours postoperatively.

    Presence or absence of postoperative nausea and vomiting (PONV) will be assessed immediately after extubation, upon arrival to the recovery room, and at 2, 8, 12, 24, and 48 hours postoperatively using direct patient questioning.

  10. Airway Pressure Parameters (Peak and Mean Airway Pressure)

    Time frame: From 1 minute to 30 minutes after airway device placement.

    Peak inspiratory pressure (PIP) will be measured and recorded at 1, 3, 5, 10, 15, and 30 minutes after airway-device insertion.

  11. Anesthesia Duration

    Time frame: Intraoperative period (approximately 60-120 minutes)

    Total duration of anesthesia will be measured from the start of induction to the transfer of the patient to the recovery unit.

  12. Surgical Duration

    Time frame: Intraoperative period (approximately 30-120 minutes)

    Duration of surgery will be recorded from the initial surgical incision to the completion of the final suture.

  13. Postoperative Laryngospasm and Bronchospasm

    Time frame: Within 24 hours post-extubation

    The incidence of postoperative laryngospasm and bronchospasm will be assessed clinically within the first 24 hours following extubation. Laryngospasm is defined as an involuntary spasm of the vocal cords resulting in airway obstruction, while bronchospasm refers to a sudden constriction of the bronchial muscles leading to respiratory distress. These conditions will be diagnosed based on clinical signs such as stridor, increased respiratory effort, reduced airflow, and desaturation (SpO₂ <90%).

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmet Ozan Aydin, M.D.

CONTACT

[email protected]

+905438956146

Hatice Selcuk KUSDERCI, M.D.

CONTACT

[email protected]

+905052159896

Sponsors and collaborators

Lead sponsor

Samsun University

Other

Registry information

Official study title

Comparison of Video Laryngeal Mask Airway and Endotracheal Tube Use for Airway Safety in Patients Undergoing Septoplasty

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 30, 2025
Registry last updated
Jun 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.